VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Active:	Yes
Cancer Type:	Melanoma	NCT ID:	NCT06264180
Trial Phases:	Phase III	Protocol IDs:	RP1-104 (primary) NCI-2024-04401
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Replimune Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06264180

Summary

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study
comparing VO in combination with nivolumab versus Physician's Choice treatment for
patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on
an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination
regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4
therapy.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.